Direct answer: Therapeutic Equivalence (TE) evaluation of the FDA and TE Code are information used by the Orange Book to describe the evaluation of therapeutic equivalence between specific multi-source prescription drugs. Final guidance issued in August 2026 explains how the FDA evaluates the equivalency and code meaning of treatment; The guide finalized a draft of the same name for 2022; the nature of the document, the current status and the business proposals are set out below; Specific products should be judged in the official language.
What is this file, at what stage?
The regulatory document and its status referred to in this paper is based on the original FDA page listing. The final guidance explains the evaluation methodology for the FDA; TE Code does not apply to generalizing clinical interchanges among all products.
A distinction should be made between binding regulations/final rules and FDA guides, drafts, discussion papers or enforcement policies. The latter have different legal effects; Specific sources of restraint are governed by the documents and by the legislation cited.
Which enterprises and products need attention?
Develop multi-source drug prescriptions, imitations or evaluation of Orange Book treatment equivalent information for pharmaceutical companies and procurement assessment teams.
It is recommended that this be confirmed on a product-business role-US market-based basis; Where product classifications or responsible subjects cannot be judged by name alone, the labels are subject to individual checks.
Where is the change from what was previously requested?
The substance of the document and the background to the previous rules are set out below. Only changes specified in official documents are considered to be changes; The recommendatory content is not to be added to the mandatory obligation.
Direct answer:Therapeutic Equivalence (TE) evaluation of the FDA and TE Code are information used by the Orange Book to describe the evaluation of therapeutic equivalence between specific multi-source prescription drugs. Final guidance issued in August 2026 explains how the FDA evaluates the equivalency and code meaning of treatment; The guide finalized the 2022 draft by the same name.
This is the final version of the CDER Level 1 guide on approved, multi-source equivalency evaluation of prescription drugs and relevant information in Orange Book. The FDA Guide generally describes the current thinking of the institution and does not create binding liability independently of the statutory or statutory obligations cited therein.
- Identification of active ingredient, formulation type, route of delivery, specifications and product-specific entries in FDA Orange Book.
- Check whether the product is in the active list of approved medicines and check the corresponding TE Code and the notes.
- Do not presume treatment equivalents based solely on the same composition or the same NDC; Verification of specific entries and their applicable conditions.
- Where procurement, development or declared decision-making involves alternative use, it is confirmed by reference to the FDA original text, state legislation, professional judgement and product labelling.
If an enterprise is preparing a US generic or multi-source drug project, the TE evaluation may affect product comparison and market information collation, but it cannot substitute for ANDA route judgement, application for review or FDA product approval. Chinese enterprises should verify the reference medicine, the agent type and the proposed declaration path before assessing the relationship between the guide and the project.
Key dates and transitional arrangements
The following dates are derived from the factual summary of the documents retained here. A distinction should be made between the date of issuance, the date of closure of comments and the date of entry into force/application of the respective documents. There is no presumption in respect of matters that are not clearly stated in the original text.
- August 2026: Date of issuance of the document (as expressed in the original language of the adjacent official).
The date of publication/update of the website’s articles does not correspond to the date of implementation of the statute; If the dates of the official pages differ, reference is made to the official document and the current FDA page.
How can Chinese companies prepare?
- Check specific products, formulation types, routes of delivery and Orange Book entries; Using TE Code as FDA evaluation information understanding is not a substitute for product-level regulatory judgement.
- Identify those responsible, sources and internal review nodes, and maintain official page versions and verification dates.
- If the official document is revised, withdrawn or the final version issued, the applicable conclusions are reassessed and the records updated.
For this purpose, the recommendation does not substitute for the obligation set out in the body of the statute.
Exceptions, pending confirmations and common misreading
- The final guidance explains the evaluation methodology for the FDA; TE Code does not apply to generalizing clinical interchanges among all products.
- When exemptions, transition periods, border products or different business actors are encountered, the original text should be consulted on the basis of specific facts; Uncertainties should be clearly identified for confirmation.
- Registration, listing, submission or obtaining of a reply should not be mistakenly referred to as FDA approval or authentication.
Official information and reconciliation records
(b) The station’s author: Mr. Toshito. Reviewer: Mr. Toto. Date of the structural review of the article: 2026-11-02; The statutory status and specific obligations are based on the official language listed.
Next
Identification of scope of application by product and corporate role, viewing Regulatory UpdatesAnd the corresponding FDA Compliance Service Scope; If you need a case judgement, you can do it. Contact PageSubmission of product information.